Harpoon Therapeutics snares $70M to focus on cancer immunotherapy

Harpoon Therapeutics Inc., a South San Francisco company working on engineered proteins that direct infection-fighting T cells to better spot and attack tumor cells, closed a $70 million Series C round. Part of the white-hot cancer immunotherapy space, where cancer patients' own immune system are amped up or refocused on invading antigens, Harpoon's "T cell engagers" are designed to direct T cells to kill cells that express specific proteins. The company's secret weapon, it says, are its initial…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news